KLRA (Kailera Therapeutics) EBIT: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics EBIT?

Kailera Therapeutics KLRA +2.24% 11 EBIT is $ Mil as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Kailera Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-158.34 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kailera Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 was -209.59%. Kailera Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,417.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Kailera Therapeutics  (NAS:KLRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kailera Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-158.34 * ( 1 - 0% )/( (5.325 + 145.767)/ 2 )
=-158.34/75.546
=-209.59 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=178.445 - 2.42 - ( 175.178 - max(0, 6.911 - 177.611+175.178))
=5.325

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=692.294 - 35.395 - ( 546.056 - max(0, 46.405 - 557.537+546.056))
=145.767

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Kailera Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-158.34/( ( (0.68 + max(-3.969, 0)) + (12.418 + max(-36.609, 0)) )/ 2 )
=-158.34/( ( 0.68 + 12.418 )/ 2 )
=-158.34/6.549
=-2,417.77 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.433) - (2.42 + 0 + 3.982)
=-3.969

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 8.756) - (35.395 + 0 + 9.97)
=-36.609

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kailera Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/1735.372
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics EBIT Related Terms

Kailera Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics EBIT Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
EBIT
0.00 -158.34

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
EBIT 0.00 -158.34

KLRA vs VCEL, NUVB, IOVA: EBIT Comparison

For the Biotechnology subindustry, Kailera Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kailera Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kailera Therapeutics's EV-to-EBIT falls into.


KLRA
11GF Score
Kailera Therapeutics Inc KLRA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
Kailera Therapeutics (KLRA) has a EBIT of $ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kailera Therapeutics.
Is Kailera Therapeutics' EBIT too high?
Kailera Therapeutics' current EBIT is $ Mil. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' EBIT compare to VCEL and NUVB?
Kailera Therapeutics' EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kailera Therapeutics. Kailera Therapeutics's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current EBIT of $ Mil. The current EBIT is $ Mil. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current EBIT is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price